<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02714634</url>
  </required_header>
  <id_info>
    <org_study_id>6020</org_study_id>
    <nct_id>NCT02714634</nct_id>
  </id_info>
  <brief_title>Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate</brief_title>
  <acronym>BIO3</acronym>
  <official_title>Randomized Controlled Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Approximately, 40 to 50% of patients with rheumatoid arthritis (RA), the most frequent&#xD;
      inflammatory arthritide, are non responders to the consensual 1st line of treatment :&#xD;
      methotrexate. In these patients, it is well demonstrated that the addition of other&#xD;
      immunomodulatory drug(s) often results in a significant improvement. However, the best option&#xD;
      regarding the drug(s) to add remains unclear. Rheumatologists are currently used to adding a&#xD;
      targeted biologic therapy, such as anti-TNFα, and more recently abatacept or tocilizumab.&#xD;
      Triple therapy using 3 conventional disease-modifying drugs (DMARDs),&#xD;
      methotrexate+salazopyrine+hydroxychloroquine could be an alternative option to biologics, all&#xD;
      the more as they have a more favorable safety profile and a much lower cost. Uncertainty&#xD;
      remains regarding the superiority of biologics on triple therapy in methotrexate insufficient&#xD;
      responders (IR). Investigators decided to address this issue by performing a randomized&#xD;
      controlled pragmatic trial.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of participant with low disease activity (DAS28-CRP&lt;3.2) and a daily dose ≤ 7.5 mg/day of equivalent prednisone</measure>
    <time_frame>At 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events rate</measure>
    <time_frame>At 3, 6, 9 and at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of hydroxychloroquine, salazopyrine and methotrexate in the triple therapy group and methotrexate, biologic and anti-drug antibody in the other group.</measure>
    <time_frame>at 6, and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical disease activity index (CDAI).</measure>
    <time_frame>At inclusion, 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DAS 28 CRP score.</measure>
    <time_frame>at inclusion, 3, 6, 9 and 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2010 ACR (American College of Rheumatology)/EULAR classification Criteria for RA, ACR 20, 50, 70 and boolean remission.</measure>
    <time_frame>at 3, 6, 9 and 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Sharp Van der Heijde score.</measure>
    <time_frame>at inclusion and at 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in comedications (dose)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in comedications (route of administration)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in comedications (drug)</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QUALISEX score at inclusion, 6 months and at 12 months.</measure>
    <time_frame>at inclusion, 6 months and at 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medico-economic costs.</measure>
    <time_frame>at inclusion, 3, 6, 9 and at 12 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment compliance</measure>
    <time_frame>at 3, 6, 9 and 12 months</time_frame>
    <description>A questionnaire will be filled by patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Insufficient Response to Methotrexate</condition>
  <arm_group>
    <arm_group_label>methotrexate + biologic group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate +&#xD;
biologic chosen by investigator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Triple therapy using 3 conventional disease modifying drugs (DMARDs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate + biologic administration</intervention_name>
    <description>Methotrexate + adalimumab or&#xD;
Methotrexate + certolizumab or&#xD;
Methotrexate + etanercept or&#xD;
Methotrexate + golimumab or&#xD;
Methotrexate + infliximab or&#xD;
Methotrexate + abatacept or&#xD;
Methotrexate + rituximab or&#xD;
Methotrexate + tocilizumab</description>
    <arm_group_label>methotrexate + biologic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate + salazopyrine + hydroxychloroquine administration</intervention_name>
    <arm_group_label>Triple therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with rheumatoid arthritis according to EULAR/ACR 2010 criteria&#xD;
&#xD;
          -  DAS28-CRP&gt;3.2&#xD;
&#xD;
          -  Insufficient response to methotrexate at a weekly dose≥15mg after at least 3 months&#xD;
&#xD;
          -  RA radiographic erosions and/or serum rheumatoid factor associated to anti-Cyclic&#xD;
             Citrullinated Peptide (Anti-CCP)&#xD;
&#xD;
          -  Age greater or equal to 18 years&#xD;
&#xD;
          -  Written informed consent, dated and signed before initiating any trial-related&#xD;
             procedure&#xD;
&#xD;
          -  Affiliation to a social insurance system&#xD;
&#xD;
          -  Women of child bearing potential, negative β-HCG assay (Human chorionic gonadotropin)&#xD;
&#xD;
          -  Effective method of birth control during the study and continuing 5 months after the&#xD;
             end of the study for men and depending for the biotherapy associated for women&#xD;
             (referred to the summary product characteristic).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with one of the evaluated biologics&#xD;
&#xD;
          -  Previous treatment with triple therapy&#xD;
&#xD;
          -  Other inflammatory arthritis except RA associated with Sjögren's syndrome&#xD;
&#xD;
          -  Contraindication to all biologics or to methotrexate, sulfasalazine and&#xD;
             hydroxychloroquine&#xD;
&#xD;
          -  Corticosteroids at a dose &gt;15 mg/d of equivalent prednisone for at least 4 weeks&#xD;
             before the inclusion&#xD;
&#xD;
          -  Absence of tuberculosis screening&#xD;
&#xD;
          -  Patient who cannot be followed during 12 months&#xD;
&#xD;
          -  Pregnancy, breastfeeding, desire of pregnancy in the 12 months&#xD;
&#xD;
          -  Drug addiction, addiction to alcohol&#xD;
&#xD;
          -  Participation in a clinical study with an investigational product within 4 weeks prior&#xD;
             to the start of the study treatment&#xD;
&#xD;
          -  Women of child bearing potential, unless they are using an effective method of birth&#xD;
             control&#xD;
&#xD;
          -  Patient under law protection&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jacques-Eric GOTTENBERG, Professor</last_name>
    <phone>3 88 12 79 53</phone>
    <phone_ext>+33</phone_ext>
    <email>jacques-eric.gottenberg@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques-Eric Gottenberg</last_name>
      <phone>3 88 12 81 89</phone>
      <phone_ext>0033</phone_ext>
      <email>jacques-eric.gottenberg@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques-Eric Gottenberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 1, 2016</study_first_submitted>
  <study_first_submitted_qc>March 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

